Why carry out this study?

Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first oncolytic immunotherapy to be approved in Europe for the local treatment of unresectable metastatic stage IIIB/C–IVM1a melanoma.

This study is the first comprehensive multinational evaluation of the use of T-VEC to treat unresectable stage IIIB/C–IVM1a melanoma in real-world clinical practice in Europe; the objectives of this study were to describe patient characteristics (demographics, clinical and melanoma disease history), use of T-VEC and other melanoma treatments, adverse events of interest, and clinical outcomes.

What was learned from the study?

Differences in the use of T-VEC between European countries were apparent, with physicians in the Netherlands using T-VEC in patients with lower disease burden and in the first-line setting, which appears to lead to potentially improved outcomes.

Favourable tolerability was observed.